These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 29149155)

  • 1. Lower Cutoffs for LC-MS/MS Urine Drug Testing Indicates Better Patient Compliance.
    Krock K; Pesce A; Ritz D; Thomas R; Cua A; Rogers R; Lipnick P; Kilbourn K
    Pain Physician; 2017 Nov; 20(7):E1107-E1113. PubMed ID: 29149155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Benefits of Direct-to-Definitive Testing for Monitoring Compliance in Pain Management.
    Gencheva R; Petrides A; Kantartjis M; Tanasijevic M; Dahlin JL; Melanson S
    Pain Physician; 2018 Nov; 21(6):E583-E592. PubMed ID: 30508989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients.
    Pesce A; Rosenthal M; West R; West C; Crews B; Mikel C; Almazan P; Latyshev S
    Pain Physician; 2010; 13(3):273-81. PubMed ID: 20495592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Illicit drug use correlates with negative urine drug test results for prescribed hydrocodone, oxycodone, and morphine.
    Pesce A; West C; Gonzales E; Rosenthal M; West R; Mikel C; Almazan P; Latyshev S; Horn P
    Pain Physician; 2012; 15(5):E687-92. PubMed ID: 22996862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of an opiate immunoassay for detecting hydrocodone and hydromorphone in urine from a clinical population: analysis of subthreshold results.
    Bertholf RL; Johannsen LM; Reisfield GM
    J Anal Toxicol; 2015; 39(1):24-8. PubMed ID: 25288720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoassay-Based Drug Tests Are Inadequately Sensitive for Medication Compliance Monitoring in Patients Treated for Chronic Pain.
    Snyder ML; Fantz CR; Melanson S
    Pain Physician; 2017 Feb; 20(2S):SE1-SE9. PubMed ID: 28226337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of medication cutoff values in a pain patient population.
    Pesce A; West C; West R; Crews B; Mikel C; Rosenthal M; Almazon P; Latyshev S
    J Opioid Manag; 2011; 7(2):117-22. PubMed ID: 21561035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of illicit drug cutoff values in a pain patient population.
    West R; Pesce AJ; Crews B; Mikel C; Rosenthal M; Almazan P; Latyshev S; West C
    Clin Chim Acta; 2011 Aug; 412(17-18):1589-93. PubMed ID: 21600890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population.
    West R; Pesce A; West C; Crews B; Mikel C; Almazan P; Rosenthal M; Latyshev S
    Pain Physician; 2010; 13(1):71-8. PubMed ID: 20119465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LC-MS/MS extends the range of drug analysis in pain patients.
    Mikel C; Almazan P; West R; Crews B; Latyshev S; Pesce A; West C
    Ther Drug Monit; 2009 Dec; 31(6):746-8. PubMed ID: 19935363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of oral fluid in compliance monitoring of opioid medications.
    Conermann T; Gosalia AR; Kabazie AJ; Moore C; Miller K; Fetsch M; Irvan D
    Pain Physician; 2014; 17(1):63-70. PubMed ID: 24452646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated Quantitative Urine Toxicology Analysis May Improve Chronic Pain Patient Compliance with Opioid Therapy.
    Knezevic NN; Khan OM; Beiranvand A; Candido KD
    Pain Physician; 2017 Feb; 20(2S):S135-S145. PubMed ID: 28226335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Illicit drug use in the pain patient population decreases with continued drug testing.
    Pesce A; West C; Rosenthal M; Mikel C; West R; Crews B; Almazan P; Latyshev S; Horn PS
    Pain Physician; 2011; 14(2):189-93. PubMed ID: 21412373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS/MS.
    West R; Mikel C; Hofilena D; Guevara M
    Drug Alcohol Depend; 2018 Dec; 193():183-191. PubMed ID: 30391868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating medicinal from illicit use in positive methamphetamine results in a pain population.
    West R; Pesce A; West C; Mikel C; Velasco J; Gonzales E; Dizon Z; Almazan P; Latyshev S
    J Anal Toxicol; 2013 Mar; 37(2):83-9. PubMed ID: 23316029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suitability of the DRI Hydrocodone/Hydromorphone Immunoassay in the Clinical Environment at a Lower Cutoff: Validation With LC-MS/MS Analysis.
    Dixon RB; Dasgupta A
    Ther Drug Monit; 2016 Dec; 38(6):787-790. PubMed ID: 27764026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine.
    Guo AY; Ma JD; Best BM; Atayee RS
    J Anal Toxicol; 2013; 37(9):636-41. PubMed ID: 24080973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a Newly Formulated Enzyme Immunoassay for the Detection of Hydrocodone and Hydromorphone in Pain Management Compliance Testing.
    Nascimento R; Poklis A; Wolf CE
    J Anal Toxicol; 2016 Oct; 40(8):583-587. PubMed ID: 27562969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.